netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

Netscientific business Vortex Bio kicks off lung cancer proof of concept trial

May 24, 2017
-
News, RNS Announcements
04:18 24 May 2017
http://www.proactiveinvestors.com/companies/news/178249/netscientific-business-vortex-bio-kicks-off-lung-cancer-proof-of-concept-trial-178249.html
These studies are designed to provide proof of principle that biomarkers used for tumour biopsises can be adapted for circulating tumour cells (CTCs).
picture of cells

Vortex aims to collect circulating turmour cells

NetScientific PLC (LON:NSCI) portfolio company Vortex Biosciences has initiated two clinical research studies with Californian university UCLA in patients with Non-Small Cell Lung Cancer (NSCLC).

These studies are designed to provide proof of principle that biomarkers used for tumour biopsises can be adapted for circulating tumour cells (CTCs).

This first 60 patient study is intended to determine if cancer causing EGFR mutations can be identified in CTCs isolated and collected using Vortex’sVTX-1 Liquid Biopsy System from NSCLC patient samples.

The second 100 NSCLC patient study is intended to show CTCs isolated using the VTX-1 Liquid Biopsy System are compatible with the PD-L1 biomarker, which can help identify patients suitable for immunotherapy treatment.

Francois  Martelet, who is chairman of Vortex a well as being NetScientific’s chief executive, said  said: “These two proof of principle clinical research studies, in collaboration with UCLA, are a vital step in clinically validating and thus commercialising the company’s first product, the VTX-1 system.”

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
Proposed Placing and Subscription, Notice of General Meeting
NEXT POST →
Proactive Investors One2One Investor Forum - London - June 15th 2017

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
Netscientific business Vortex Bio kicks off lung cancer proof of concept trial - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT